ANXA1 and prostate carcinoma: Decreased expression of ANXA1 has been shown to be responsible for a strong delay of proliferation, migration/invasion, and angiogenesis in melanoma, lung carcinoma, NSCLC, breast cancer, and prostate cancer models [22].